168 related articles for article (PubMed ID: 38775844)
1. Cholesterol neutralized vemurafenib treatment by promoting melanoma stem-like cells via its metabolite 27-hydroxycholesterol.
Wang X; Zhong F; Chen T; Wang H; Wang W; Jin H; Li C; Guo X; Liu Y; Zhang Y; Li B
Cell Mol Life Sci; 2024 May; 81(1):226. PubMed ID: 38775844
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
Zubrilov I; Sagi-Assif O; Izraely S; Meshel T; Ben-Menahem S; Ginat R; Pasmanik-Chor M; Nahmias C; Couraud PO; Hoon DS; Witz IP
Cancer Lett; 2015 May; 361(1):86-96. PubMed ID: 25725450
[TBL] [Abstract][Full Text] [Related]
3. Host CYP27A1 expression is essential for ovarian cancer progression.
He S; Ma L; Baek AE; Vardanyan A; Vembar V; Chen JJ; Nelson AT; Burdette JE; Nelson ER
Endocr Relat Cancer; 2019 Jul; 26(7):659-675. PubMed ID: 31048561
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.
Molnár E; Garay T; Donia M; Baranyi M; Rittler D; Berger W; Tímár J; Grusch M; Hegedűs B
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514305
[TBL] [Abstract][Full Text] [Related]
5. 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.
Ma L; Wang L; Nelson AT; Han C; He S; Henn MA; Menon K; Chen JJ; Baek AE; Vardanyan A; Shahoei SH; Park S; Shapiro DJ; Nanjappa SG; Nelson ER
Cancer Lett; 2020 Nov; 493():266-283. PubMed ID: 32861706
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
7. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
8. CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway.
Jiang S; Jiang T; Huang H; Chen X; Li L; Wang Z; Fei J; Liu C; Liu Z; Cheng Y
Chem Biol Interact; 2022 Jan; 351():109747. PubMed ID: 34813779
[TBL] [Abstract][Full Text] [Related]
9. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
10. Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.
Kimbung S; Chang CY; Bendahl PO; Dubois L; Thompson JW; McDonnell DP; Borgquist S
Endocr Relat Cancer; 2017 Jul; 24(7):339-349. PubMed ID: 28442559
[TBL] [Abstract][Full Text] [Related]
11. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
[TBL] [Abstract][Full Text] [Related]
12. 27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.
Dambal S; Alfaqih M; Sanders S; Maravilla E; Ramirez-Torres A; Galvan GC; Reis-Sobreiro M; Rotinen M; Driver LM; Behrove MS; Talisman TJ; Yoon J; You S; Turkson J; Chi JT; Freeman MR; Macias E; Freedland SJ
Mol Cancer Res; 2020 May; 18(5):671-684. PubMed ID: 32019810
[TBL] [Abstract][Full Text] [Related]
13. Our evolving understanding of how 27-hydroxycholesterol influences cancer.
Ma L; Cho W; Nelson ER
Biochem Pharmacol; 2022 Feb; 196():114621. PubMed ID: 34043965
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte-generated 27-hydroxycholesterol promotes the growth of melanoma by activation of estrogen receptor alpha.
Tian W; Pang W; Ge Y; He X; Wang D; Li X; Hou H; Zhou D; Feng S; Chen Z; Yang Y
J Cell Biochem; 2018 Mar; 119(3):2929-2938. PubMed ID: 29130512
[TBL] [Abstract][Full Text] [Related]
15. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.
Nelson ER; Wardell SE; Jasper JS; Park S; Suchindran S; Howe MK; Carver NJ; Pillai RV; Sullivan PM; Sondhi V; Umetani M; Geradts J; McDonnell DP
Science; 2013 Nov; 342(6162):1094-8. PubMed ID: 24288332
[TBL] [Abstract][Full Text] [Related]
16. CYP27A1 inhibits bladder cancer cells proliferation by regulating cholesterol homeostasis.
Liang Z; Chen Y; Wang L; Li D; Yang X; Ma G; Wang Y; Li Y; Zhao H; Liang Y; Niu H
Cell Cycle; 2019 Jan; 18(1):34-45. PubMed ID: 30563407
[TBL] [Abstract][Full Text] [Related]
17. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
18. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
[TBL] [Abstract][Full Text] [Related]
19. Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel.
Thang ND; Nghia PT; Kumasaka MY; Yajima I; Kato M
Asian Pac J Cancer Prev; 2015; 16(2):699-705. PubMed ID: 25684511
[TBL] [Abstract][Full Text] [Related]
20. Increased 27-hydroxycholesterol production during luteolysis may mediate the progressive decline in progesterone secretion.
Xu Y; Hutchison SM; Hernández-Ledezma JJ; Bogan RL
Mol Hum Reprod; 2018 Jan; 24(1):2-13. PubMed ID: 29177442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
